Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 142   

Articles published

NVS 100.40 +0.84 (0.84%)
price chart
Novartis AG (ADR) Slapped With $110 Million Gender Discrimination Lawsuit
Novartis AG (ADR) (NYSE:NVS) will have to defend itself in US courts over claims that the Swiss-based drug giant has routinely denied female employees at its US division equal pay and career growth opportunities.
Novartis Involved in Another Gender Discrimination Lawsuit
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (NYSE:NVS) & GlaxoSmithKline PLC (NYSE:GSK) Receive a Green ...
Arrowhead Research Corp To Acquire Novartis AG (ADR) RNAi Assets
Arrowhead Research Corp (NASDAQ:ARWR), which develops targeted RNAi therapeutics, announced Thursday that it will acquire Novartis AG's (ADR) (NYSE:NVS) RNAi research and development portfolio and other assets in efforts to strengthen its work in ...
Small Cap Stocks Under Consideration - Arrowhead Research (ARWR),Neustar ...  Investor Wired
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
Novartis AG (ADR) Ordered To Halt Some Japanese Operations
The Japanese Health Ministry has ordered Novartis AG ADR (NYSE: NVS) to halt most of its operations in Japan for 15 days in March, claiming that the company had failed to report side-effects caused by its products within a pre-specified time.
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Novartis AG (ADR) Heart Failure Drug Granted FDA Priority Review
Novartis AG (ADR) (NYSE:NVS), a world leader in the research and development of healthcare products, announced Friday that its novel heart failure drug, LCZ696, has been granted a Priority Review designation by the US Food and Drug Administration ...
Novartis AG (ADR), GlaxoSmithKline plc (ADR) Recieve Final Approval For Thee ...
According to the US Federal Trade Commission's (FTC) announcement yesterday, Novartis (NYSE:NVS) has received the US antitrust regulator's approval to acquire drugs from Glaxo's oncology portfolio, contingent upon certain specified conditions.
Novartis AG (ADR) (NYSE:NVS) Update: FDA approves Farydak for treatment of ...
Novartis AG (ADR) (NYSE:NVS) Update based on the information released on Monday, Feb 23rd, FDA approves Farydak for treatment of multiple myeloma.
Novartis AG (ADR) Wins FDA Approval For Blood Cancer Drug  Bidness ETC
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog  Nasdaq
Novartis AG (ADR) (NVS)'s Cosentyx Gets Clearance In Europe
Novartis AG (ADR) (NYSE:NVS)'s Cosentyx� gets the European Commission approval to be the first-line treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy.
Stock Watch: Novartis AG (ADR) (NYSE:NVS), MGIC Investment Corp. (NYSE ...  Realist Investor
Novartis Gets European Approval For Potential Blockbuster Cosentyx  Bidness ETC